Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Liuying Township, Taiwan Clinical Trials

A listing of Liuying Township, Taiwan clinical trials actively recruiting patients volunteers.

RESULTS

Found (1955) clinical trials

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.  

Phase

The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.  

Phase

Phase 1/1b to establish the maximum tolerated dose of the combination of study drugs in patients with advanced solid tumor malignancies with a KRAS G12C mutation. Phase 2 to evaluate clinical activity of the combination of study drugs in selected solid tumor malignancies with KRAS G12C mutation.  

Phase

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.  

Phase

This is an open-label, multicenter, Phase 1b platform study in subjects with advanced or metastatic solid tumors (Part 1a) and subjects with selected solid tumors (Part 1b and Part 2). Two treatment groups (Group A and Group B) will be evaluated. Part 1a utilizes a 3+3 design to evaluate pembrolizumab …

Phase

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

The study comprises four open-label substudies in patients with advanced urothelial cancer harboring FGFR GA who will be treated by single-agent derazantinib or derazantinib in combination with atezolizumab. The study enrolls patients with cisplatin-ineligible status, or patients whose disease progressed after either first-line treatment or prior treatment with FGFR inhibitors.

Phase

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

The Part I (Phase I) will evaluate the safety of the MB-CART19.1 and determine the recommended dose levels for the Part II (Phase II) efficacy evaluation in each of the three disease cohorts. Dose evaluation will start in Cohorts 1 and 2 with Dose Level 1 and in Cohort 3 …

Phase

Study of TPX-0046 A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Phase 1 Dose Escalation: To evaluate the overall safety profile, characterize the PK profiles and assess the preliminary efficacy of TPX-0046 in adults subjects with advanced solid tumors harboring oncogenic RET fusions or mutations. Food Effect Sub-Study: To determine the effect of food on PK of TPX-0046 in adult subjects …

Phase

High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease

Chronic Granulomatous Disease (CGD) is an inherited disorder resulting from a failure to produce nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, necessary for protection against a number of infectious organisms. Patients are subject to recurrent infections and inflammatory complications. The current management of these participants is limited to close surveillance for …

Phase

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myeloma when used in conjunction with granulocyte-colony stimulating factor (G-CSF). The drug s mechanism of action is the …

Phase